Revolutionary Nanotechnology Granted FDA Approval for Clinical Trials in Cancer Treatment

In a groundbreaking announcement, New Phase CEO Ofer Shalev revealed that the company has been granted FDA approval to carry out clinical trials on its technology aimed at transforming late-stage cancer from a fatal disease to a chronic one. This revolutionary approach not only extends life expectancy but also improves the quality of life for patients by managing symptoms without harsh side effects commonly associated with current treatment options.

The innovative treatment developed by New Phase leverages its patented Sarah Nanotechnology System, which distinguishes between cancerous and healthy cells, allowing it to specifically target and destroy cancer cells while minimizing damage to healthy cells. By using nanoparticles injected intravenously and directed to tumor sites, followed by exposure to an alternating magnetic field, cancer cells are heated and eliminated, all while maintaining temperature control.

This systemic treatment is designed to not only target specific tumors but also eradicate cancer cells throughout the body, including micrometastases and multiple tumors that often arise in advanced stages of cancer. New Phase has already conducted successful trials on 20 patients with various types of cancer at the Rabin Medical Center in Israel. After FDA approval, the company plans to carry out clinical trials at a US hospital with the goal of bringing this revolutionary treatment to market by 2027.

New Phase was co-founded by Ofer Shalev and Dr. Rafi Hof in 2013 with a personal mission behind its technology as Dr. Hof lost his mother to cancer, leading to the creation of the Sarah Nanotechnology system. The company, located in Petah Tikva near Rabin Medical Center, has raised $34 million in funding from investors in Israel, the United States, and Brazil.